Search

Your search keyword '"Koller, Paul"' showing total 13 results
Start Over Author "Koller, Paul" Publisher wiley
13 results on '"Koller, Paul"'

1. Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia

Author

Othman, Tamer, primary, Koller, Paul, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Ngo, Dat, additional, Tinajero, Jose, additional, Ali, Haris, additional, Cai, Ji‐Lian, additional, Mei, Matthew, additional, Aribi, Ahmed, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Pullarkat, Vinod, additional, and Aldoss, Ibrahim, additional

Published
2024
Full Text
View/download PDF

2. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia

Author

Othman, Tamer, primary, Li, Shanpeng, additional, Zhang, Jianying, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Ngo, Dat, additional, Chen, Jason, additional, Farol, Leonardo, additional, Sahebi, Firoozeh, additional, Sandhu, Karamjeet, additional, Spielberger, Ricardo, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Stein, Anthony S., additional, Nakamura, Ryotaro, additional, Pullarkat, Vinod, additional, Mei, Matthew, additional, Aldoss, Ibrahim, additional, and Koller, Paul, additional

Published
2024
Full Text
View/download PDF

3. Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer

Author

Pourhassan, Hoda, primary, Zhang, Jianying, additional, Tinajero, Jose, additional, Pullarkat, Vinod, additional, Agrawal, Vaibhav, additional, Koller, Paul, additional, Al Malki, Monzr, additional, Aribi, Ahmed, additional, Salhotra, Amandeep, additional, Sandhu, Karamjeet, additional, Ali, Haris, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Forman, Stephen, additional, and Aldoss, Ibrahim, additional

Published
2024
Full Text
View/download PDF

4. Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID ‐19: A retrospective single‐center experience

Author

Amanam, Idoroenyi, primary, Yao, Janny, additional, Puing, Alfredo, additional, Tsai, Ni‐Chun, additional, Samuels, Diana, additional, Ngo, Dat, additional, Ho, Stephanie, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Arslan, Shukaib, additional, Artz, Andrew, additional, Htut, Myo, additional, Koller, Paul, additional, Salhotra, Amandeep, additional, Sandhu, Karamjeet, additional, Nikolaenko, Liana, additional, Pawlowska, Anna, additional, Shouse, Geoffrey, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Forman, Stephen, additional, Nakamura, Ryotaro, additional, Dadwal, Sanjeet, additional, and Al Malki, Monzr M., additional

Published
2023
Full Text
View/download PDF

5. High Response Rates and Transition to Transplant after Novel Targeted and Cellular Therapies in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia with Philadelphia‐Like Fusions

Author

Aldoss, Ibrahim, primary, Afkhami, Michelle, additional, Yang, Dongyun, additional, Gu, Zhaohui, additional, Mokhtari, Sally, additional, Shahani, Shilpa, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Koller, Paul, additional, Arslan, Shukaib, additional, Tomasian, Vanina, additional, Al Malki, Monzr M., additional, Artz, Andrew, additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Ball, Brian, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Becker, Pamela S., additional, Stewart, Forrest M., additional, Curtin, Peter, additional, Smith, Eileen, additional, Telatar, Milhan, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Nakamura, Ryotaro, additional, and Pullarkat, Vinod, additional

Published
2023
Full Text
View/download PDF

6. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia

Author

Salhotra, Amandeep, primary, Tsai, Ni‐Chun, additional, Zhang, Jianying, additional, Ngo, Dat, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet, additional, Ball, Brian, additional, Al‐Malki, Monzr, additional, Ali, Haris, additional, Koller, Paul, additional, Artz, Andrew, additional, Forman, Stephen, additional, Nakamura, Ryotaro, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Aldoss, Ibrahim, additional, and Pullarkat, Vinod, additional

Published
2021
Full Text
View/download PDF

7. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia

Author

Aldoss, Ibrahim, primary, Otoukesh, Salman, additional, Zhang, Jianying, additional, Mokhtari, Sally, additional, Ngo, Dat, additional, Mojtahedzadeh, Mona, additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Arslan, Shukaib, additional, Koller, Paul, additional, Ball, Brian, additional, Stewart, Forrest, additional, Curtin, Peter, additional, Artz, Andrew, additional, Nakamura, Ryotaro, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Stein, Anthony S., additional, and Pullarkat, Vinod, additional

Published
2021
Full Text
View/download PDF

8. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax ( HMA‐Ven ) or liposomal daunorubicin‐cytarabine ( CPX ‐351)

Author

Salhotra, Amandeep, primary, Aribi, Ahmed, additional, Ngo, Dat, additional, Zhang, Jianying, additional, Sandhu, Karamjeet, additional, Al‐Malki, Monzr, additional, Ali, Haris, additional, Koller, Paul, additional, Arslan, Shukaib, additional, Budde, Elizabeth, additional, Khaled, Samer, additional, Dadwal, Sanjeet, additional, Snyder, David S., additional, Artz, Andrew, additional, Forman, Stephen, additional, Nakamura, Ryotaro, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Aldoss, Ibrahim, additional, and Pullarkat, Vinod, additional

Published
2021
Full Text
View/download PDF

9. GATA3 rs3824662A allele in B‐cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis

Author

Koller, Paul B., primary, Zhang, Hui, additional, Kantarjian, Hagop, additional, Jabbour, Elias, additional, Pierce, Sherry, additional, Gocho, Yoshihiro, additional, Roberts, Kathryn G., additional, Yang, Wenjian, additional, Mullighan, Charles G., additional, Yang, Jun, additional, Konopleva, Marina, additional, and Jain, Nitin, additional

Published
2020
Full Text
View/download PDF

10. Venetoclax and hypomethylating agents inFLT3‐mutated acute myeloid leukemia

Author

Aldoss, Ibrahim, primary, Zhang, Jianying, additional, Mei, Matthew, additional, Al Malki, Monzr M, additional, Arslan, Shukaib, additional, Ngo, Dat, additional, Aribi, Ahmed, additional, Ali, Haris, additional, Sandhu, Karamjeet, additional, Salhotra, Amandeep, additional, Koller, Paul, additional, Khaled, Samer, additional, Artz, Andrew, additional, Snyder, David, additional, Nakamura, Ryotaro, additional, Forman, Stephen J, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, and Pullarkat, Vinod, additional

Published
2020
Full Text
View/download PDF

11. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

Author

Koller, Paul B., primary, Kantarjian, Hagop M., additional, Nogueras‐Gonzalez, Graciela M., additional, Jabbour, Elias, additional, Verstovsek, Srdan, additional, Borthakur, Gautam, additional, Estrov, Zeev, additional, Wierda, William G., additional, Garcia‐Manero, Guillermo, additional, Ferrajoli, Alessandra, additional, Ravandi, Farhad, additional, O'Brien, Susan M., additional, and Cortes, Jorge E., additional

Published
2016
Full Text
View/download PDF

12. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.

Author

Aldoss I, Otoukesh S, Zhang J, Mokhtari S, Ngo D, Mojtahedzadeh M, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Koller P, Ball B, Stewart F, Curtin P, Artz A, Nakamura R, Marcucci G, Forman SJ, Stein AS, and Pullarkat V

Subjects
Humans, Recurrence, Retrospective Studies, Antibodies, Bispecific therapeutic use, Disease Progression, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Abstract

Background: Blinatumomab has demonstrated encouraging activity in relapsed/refractory (r/r) and minimal residual disease-positive (MRD+) acute lymphoblastic leukemia (ALL). Extramedullary disease (EMD) relapse or relapse with CD19- disease has been observed after blinatumomab therapy in patients with r/r or MRD+ ALL. However, the pathophysiology and risk factors of treatment failure are not fully understood., Methods: This study retrospectively reviewed the outcomes of adult patients with B-cell ALL treated with blinatumomab (n = 132) for either r/r (n = 103) or MRD+ disease (n = 29) at the authors' center (2013-2021) and analyzed factors associated with treatment response and EMD failure., Results: The overall response rate was 64%. A lower marrow blast burden before blinatumomab (P = .049) and no history of previous EMD (P = .019) were significantly associated with a higher response. Among the patients who responded to blinatumomab, 56% underwent consolidation with allogeneic transplantation. Blinatumomab failure was observed in 89 patients; 43% of these patients (n = 38) either progressed or relapsed at extramedullary sites. A history of extramedullary involvement (53% vs 24%; P = .005) and retention of CD19 expression at the time of relapse/progression (97% vs 74%; P = .012) were associated with a higher risk for extramedullary failure. Central nervous system (CNS) failure after blinatumomab was encountered in 39% of the patients with EMD., Conclusions: A history of EMD predicted an inferior response to blinatumomab therapy with a higher risk for relapse/progression at extramedullary sites (particularly CNS). Consolidation with allogenic transplantation in patients who primarily responded to blinatumomab did not abrogate the risk of extramedullary relapse. The incorporation of extramedullary assessment and the intensification of CNS prophylaxis may help in addressing extramedullary failure., Lay Summary: Extramedullary failure is common during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. A history of extramedullary disease predicts an inferior response to blinatumomab therapy and a higher risk for relapse/progression at extramedullary sites. Most extramedullary failure cases retain CD19 expression., (© 2021 American Cancer Society.)

Published
2022
Full Text
View/download PDF

13. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.

Author

Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, and Cortes JE

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, Disease-Free Survival, Female, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive epidemiology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Male, Middle Aged, Skin Neoplasms epidemiology, Skin Neoplasms pathology, Imatinib Mesylate therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Protein Kinase Inhibitors therapeutic use, Skin Neoplasms drug therapy
Abstract

Background: Some patients with chronic myeloid leukemia (CML) have a history of previous malignancies. To the authors' knowledge, outcomes for CML diagnosed in these patients have not been well described. The current study was conducted to determine the outcome of patients with CML and a history of prior malignancies., Methods: The current study included patients who were enrolled in clinical trials of tyrosine kinase inhibitors as initial therapy for CML in chronic phase from July 2000 to January 2014., Results: Of the 630 patients with CML who were treated with frontline tyrosine kinase inhibitors, 626 had a known prior malignancy status. Of these, 45 patients (7%) had a prior malignancy other than nonmelanoma skin cancer whereas 17 patients (3%) had a history of nonmelanoma skin cancers alone. Characteristics of CML were similar between the patients with no prior malignancy, those with a prior malignancy, and those with nonmelanoma skin cancer. Patients with a prior malignancy were found to have an older median age compared with the other 2 groups. The most common prior malignancies were nonmelanoma skin cancer in 20 patients, breast cancer in 11 patients, melanoma in 7 patients, prostate cancer in 6 patients, and colorectal cancer in 5 patients. With regard to CML, the event-free survival, transformation-free survival, and failure-free survival rates were found to be similar between the groups. There was a statistically significantly decreased survival in the group with a prior malignancy versus the group with no prior malignancy versus the group with nonmelanoma skin cancer. In a multivariate analysis, advanced age and an elevated creatinine level were found to be associated with worse survival after a diagnosis of CML., Conclusions: Patients with CML with a history of prior malignancies appear to have the same excellent outcome as patients with no prior malignancies. In the few instances in which concomitant therapy for other malignancies was required during therapy with tyrosine kinase inhibitors, this was able to be accomplished without significant toxicity. Cancer 2017;123:609-616. © 2016 American Cancer Society., Competing Interests: of conflicts of interest: J.C. has received research grants from Novartis, BMS, Ariad, Teva and Pfizer. J.C. is a consultant for Novartis, BMS, Pfizer, and Ariad. The remaining authors declare no competing financial interests., (© 2016 American Cancer Society.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results